| Oxprenolol vs placebo | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 24% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiac event (fatal and non fatal ) | 0.87 [0.65 1.17] | p=1.00 | 0 | 1103 | 1 | Taylor , | | reinfarction | 0.84 [0.58 1.22] | p=1.00 | 0 | 2076 | 2 | Schwartz (high risk and low risk) ,Taylor , | | Sudden death | 1.07 [0.61 1.89] | p=1.00 | 0 | 1741 | 1 | EIS , | | cardiovascular events | no data | | Cardiovascular death | 0.91 [0.64 1.29] | p=1.00 | 0 | 2714 | 2 | EIS ,Schwartz (high risk and low risk) , | | myocardial infarction (fatal and non fatal) | 0.76 [0.58 0.99] | p=0.04 | 0 | 2076 | 2 | Schwartz (high risk and low risk) ,Taylor , | | cardiac death | 1.67 [0.89 3.14] | p=1.00 | 0 | 1741 | 1 | EIS , | | All cause death | 0.94 [0.73 1.21] | p=1.00 | 0 | 3817 | 3 | EIS ,Schwartz (high risk and low risk) ,Taylor , |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
